Directory

Directory

Tan-Koi Wei Chuen

Assistant Professor, Centre of Regulatory Excellence

weichuen.tankoi@duke-nus.edu.sg

65161679

About

Professional

Research Interests

Teaching

Publications

Bio

Assistant Professor Tan-Koi Wei Chuen serves as Lead for Regulatory Systems Strengthening at the Centre of Regulatory Excellence (CoRE), Duke–NUS Medical School. Her research programme spans health policy and regulatory science, with a focus on policy innovation and regulatory systems strengthening as mechanisms to optimise access to safe, efficacious, well-performing and cost-effective biomedical innovations. She serves as consultant and faculty for international regulatory systems strengthening projects and training programmes in vaccine and diagnostics regulation, commissioned by the ASEAN Vaccine Security and Self-Reliance initiative, the Asian Development Bank, and the Gates Foundation. Prior to her current appointment, Asst Prof Tan-Koi held the position of Regulatory Consultant at the Health Sciences Authority of Singapore, where she also served as Team Lead for the Regulatory Research (Pharmacogenomics) and Risk Communication teams.

Education

Doctor of Philosophy

National University of Singapore, Singapore

Professional Appointment(s)

Regulatory Consultant and Team Lead of the Risk Communication and Regulatory Research Unit;

Health Sciences Authority, 01/2008 - 10/2019

Content Expert

Lee Kong Chian School of Medicine, Nanyang Technological University, 01/2016 - 12/2019

Lecturer

National Collaborative Prescribing Program, National University of Singapore, 01/2018 - 12/2018

Membership

Member

Pharmacy Society of Singapore, Currently Active

Voting Delegate

US Pharmacopoeia (USP), Currently Active

Research Interests

Assistant Professor Tan-Koi's research in health policy and regulatory science examines approaches and factors to facilitate equitable and timely access to safe, efficacious, well-performing and cost-effective biomedical innovations in precision medicine, infectious diseases, and maternal and child health. Her work is disseminated through peer-reviewed manuscripts, book chapters, policy briefs, and market insight reports.

Main Research Areas

• Health policy innovation — Examine policy levers to accelerate timely access to biomedical innovations at the health-system level, with particular emphasis on vaccines, diagnostics, and genetic tests.

• Regulatory systems strengthening — Develop approaches to enhance regulatory capacity and systems strengthening, with a focus on low- and middle-income country settings.

• Evidence-to-practice translation — Advance the uptake of research evidence into regulatory and public health practice, including tailored approaches for genetic testing, post-market safety surveillance, and mechanisms to strengthen regulator–patient engagement.

Teaching

Faculty member of international workshops and post-graduate education.

• ASEAN Vaccine Security and Self-Reliance (AVSSR): Vaccine Human Resource Development Program for Enhancing Vaccine Development and Deployment Capacities in ASEAN Countries

• Duke-NUS Medical School Centre of Regulatory Excellence Graduate Certificate

• Duke-NUS Medical School Masters of International Translational Medicine

• NUS Yong Loo Lin School of Medicine Master of Science in Precision Health & Medicine

• NUS Yong Loo Lin School of Medicine Master of Science in Applied Biomedicine

Publications

Regulatory factors affecting sustainable vaccine manufacturing in Asia and the Pacific: Findings from a scoping review and semi-structured interviews.

Vaccine – Chan Mei Xuan Jessalyn; Khoo Yoong Khean; Stona Anne-Claire; Joarder Taufique; de Alwis Ruklanthi; Vogel Silke; Lim John C W; Tan-Koi Wei Chuen (2025)

63 127607-N.A

Directory

Bio

Education

Doctor of Philosophy

Professional Appointment(s)

Regulatory Consultant and Team Lead of the Risk Communication and Regulatory Research Unit;

Content Expert

Lecturer

Membership

Member

Voting Delegate

Research Interests

Teaching

Publications

Regulatory factors affecting sustainable vaccine manufacturing in Asia and the Pacific: Findings from a scoping review and semi-structured interviews.

Regional cooperation on pandemic preparedness and vaccine equity from an economic, regulatory and legal perspective.

Regulation in the age of calamity: Changing the regulatory paradigm.

Regulatory Strengthening as a Pillar of Health System Resilience for Sustainable Immunization.

Promoting collaboration of regulators and patients in improving drug safety and regulatory decision making.

Pandemic Vaccine Development

Enhancing Vaccine Regulation for Pandemic Preparedness

Ensuring Sustainable, Locally Relevant Vaccine R&D in Resource-Limited Settings

Pharmacovigilance activities in ASEAN countries.

Role of pharmacogenetics in public health and clinical health care: a SWOT analysis.

Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore.

Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approach.

Applications of pharmacogenomics in regulatory science: a product life cycle review.

Health regulatory communications of well-established safety-related pharmacogenomics associations in six developed countries: an evaluation of alignment.

Post-vaccination abscess requiring surgical drainage in a tertiary children's hospital in Singapore.

Is HLA-B*58:01 genotyping cost effective in guiding allopurinol use in gout patients with chronic kidney disease?

The importance of ethnicity definitions and pharmacogenomics in ethnobridging and pharmacovigilance

A cluster of Epoetin-associated pure red cell aplasia: clinical features and the possible association of HLA-DRB1*12:02.

Pharmacogenetics through a public health lens: from policy to practice.

Browser not supported

Modern websites need modern browsers